| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the NMR Research Unit (Drs. Brex, Molyneux, Thompson, and Miller), Institute of Neurology, University College London, Lysholm Department of Radiology (Dr. Smiddy), The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; MR-MS centre (Drs. Barkhof and Polman), VU Medical Centre, Amsterdam, the Netherlands; Neuroimaging Research Unit (Dr. Filippi), Department of Neuroscience, Scientific Institute San Raffaele, University of Milan, Italy; Department of Neuroradiology (Dr. Yousry), Klinikum Gosshadern, Munich, Germany; Institut for Röntgendiagnostik (Dr. Hahn), Universitat Würzberg, Germany; Department of Neurology (Dr. Rolland), Centre Hospitalier, Universitaire, Rennes, France; Department of Neurology (Dr. Salonen), University of Helsinki, Finland; Department of Neurology (Dr. Pozzilli), La Sapienza, Rome, Italy; and Department of Neurology (Dr. Kappos), University Hospitals, Kantonsspittal, Basal, Switzerland.
Address correspondence and reprint requests to Dr. D.H. Miller, NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK; e-mail: d.miller{at}ion.ucl.ac.uk
Background: After the resolution of contrast enhancement, the majority of new MS lesions become isointense with surrounding white matter on T1-weighted MRI. Less commonly, a hypointense T1 lesion develops, representing the development of more severe focal tissue damage. Interferon beta (IFNß) reduces both the number of new enhancing lesions and the duration of contrast enhancement.
Objective: To determine if IFNß affects the degree of tissue damage within new lesions and if its effects are related to lesion size.
Methods: One hundred twenty-five patients with secondary progressive MS from seven European sites were randomized to receive either IFNß-1b or placebo. Monthly, contrast-enhanced T1-weighted MR images were acquired at baseline, at months 1 to 6, and at months 19 to 24. The size of all new enhancing lesions developing between months 1 and 6 was recorded and their appearance at follow-up documented.
Results: In the first 6 months, fewer new enhancing lesions occurred in the IFNß-1b arm. This difference was greater for small (70% decrease) than for large (46% decrease) lesions. Hypointense T1 lesions were more likely to form from large (25%) than from small (9%) enhancing lesions in both treatment arms. Patients taking IFNß-1b developed fewer hypointense T1 lesions; however, the proportion of enhancing lesions developing into hypointense T1 lesions was similar in both arms.
Conclusion: IFNß-1b reduced the number of new enhancing lesions, with a greater effect on small lesions. However, when a new enhancing lesion did become established, treatment with IFNß-1b did not alter its subsequent course.
This article has been cited by other articles:
|
|
 |
|
  M. Riva, V.N. Ikonomidou, J.J. Ostuni, P. van Gelderen, S. Auh, J.M. Ohayon, F. Tovar-Moll, N.D. Richert, J.H. Duyn, and F. Bagnato Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis-Induced Damage AJNR Am. J. Neuroradiol., August 1, 2009; 30(7): 1394 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cadavid, L. J. Wolansky, J. Skurnick, J. Lincoln, J. Cheriyan, K. Szczepanowski, S. S. Kamin, A. R. Pachner, J. Halper, and S. D. Cook Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study Neurology, June 9, 2009; 72(23): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. van den Elskamp, J Lembcke, V Dattola, K Beckmann, C Pohl, W Hong, R Sandbrink, K Wagner, D. Knol, B Uitdehaag, et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 764 - 769. [Abstract] [PDF]
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF]
|
|
|
|
|
|
S. Di Rezze, S. Gupta, V. Durastanti, E. Millefiorini, C. Pozzilli, and F. Bagnato An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 343 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Maier, A. V. Kuhnert, N. Taheri, M. B. Sattler, M. K. Storch, S. K. Williams, M. Bahr, and R. Diem Effects of Glatiramer Acetate and Interferon-{beta} on Neurodegeneration in a Model of Multiple Sclerosis: A Comparative Study Am. J. Pathol., October 1, 2006; 169(4): 1353 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 658 - 668. [Abstract] [PDF]
|
|
|
|
 |
|
 R. T. Naismith and A. H. Cross Multiple Sclerosis and Black Holes: Connecting the Pixels Arch Neurol, November 1, 2005; 62(11): 1666 - 1668. [Full Text] [PDF]
|
|
|
|
|
|
F. Bagnato, S. Gupta, N. D. Richert, R. D. Stone, J. M. Ohayon, J. A. Frank, and H. F. McFarland Effects of Interferon Beta-1b on Black Holes in Multiple Sclerosis Over a 6-Year Period With Monthly Evaluations Arch Neurol, November 1, 2005; 62(11): 1684 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Allie, L. Hu, K. M. Mullen, S. Dhib-Jalbut, and P. A. Calabresi Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy Arch Neurol, June 1, 2005; 62(6): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Morgen, A L. Crawford, R D Stone, R Martin, N D Richert, J A Frank, and H F McFarland Contrast-enhanced MRI lesions during treatment with interferon{beta}-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 146 - 148. [Abstract] [PDF]
|
|
|
|
|
|
K. Biernacki, J. P. Antel, M. Blain, S. Narayanan, D. L. Arnold, and A. Prat Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis Arch Neurol, April 1, 2005; 62(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inglese, J.H.T.M. van Waesberghe, M. Rovaris, K. Beckmann, F. Barkhof, D. Hahn, L. Kappos, D.H. Miller, C. Polman, C. Pozzilli, et al. The effect of interferon {beta}-1b on quantities derived from MT MRI in secondary progressive MS Neurology, March 11, 2003; 60(5): 853 - 860. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
